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Abstract
In this chapter, a historical overview as well as an overview of state of the art 
of the surgical techniques for the treatment of lung cancer is outlined. The chapter 
focuses on the introduction of open surgery, video-assisted thoracic surgery (VATS), 
uniportal VATS (UVATS), and robotic-assisted thoracic surgery (RATS) techniques 
for lung resections. A short introduction on upcoming techniques and modalities is 
given. The currently available tools as three-dimensional (3D) computed tomogra-
phy (CT), virtual reality, and endo-bronchial surgery will be discussed. Based on the 
current development, this chapter attempts to delineate the horizon of oncological 
lung surgery. The information is generated not only from the available literature, 
but also from the experiences of surgeons and other physicians as well as co-workers 
involved in lung cancer treatment around the world. This chapter can be seen as a 
general introduction to several aspects of oncological lung surgery.
Keywords: lung cancer, lung surgery, VATS, UVATS, RATS, thoracotomy, virtual 
reality, endo-bronchial surgery
1. Introduction
For centuries, the inside of the chest cavity was a no-go area for complex surgical 
interventions. The problems of an open pneumothorax were already known by the 
ancient Greek Celsus around the year 30 AD noted: “as soon as the knife really pen-
etrates to the chest, by cutting through the transverse septum, a sort of membrane 
which divides the upper from the lower parts, the man loses his life at once” [1].
At that time, drainage of an empyema as described by Hippocrates (approx. 
460–375 BC) was the only feasible operation [2]. The first report of a successful 
lung resection is attributed to Roland of Parma in 1499 who resected the herniating 
part of a lung, days after a penetrating chest trauma [3]. In 1846, general anesthesia 
with ether had been introduced by William Morton in Boston, an extremely impor-
tant step in the history of surgery.
During the mid-nineteenth century, when tuberculosis reached its highest 
incidence, it was recognized that a state of rigidity of the mediastinum permitted an 
open pneumothorax. Estlander of Helsingfors was one of the first to describe wide 
thoracoplasty in order to “rest” a lung affected by tuberculosis (“decostalisation of 
the chest” in 1879) [4].
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During the late nineteenth century, many experiments were carried out, mainly 
in animals, aimed at performing lobectomy and pneumonectomy. Usually these 
experiments were done in stages, the first procedure aiming at creating a state of 
fixation of the mediastinum. The world still was not ready yet for primary lung 
resections.
Further in this chapter, a historical overview and an overview of modern surgi-
cal techniques for the treatment of lung cancer are outlined. The focus is on the 
introduction of open surgery as well as the minimally invasive surgery. In addition, 
a short introduction to upcoming techniques and modalities is given.
2. The evolution of thoracic surgery: a journey through time
2.1  The first giant steps: aseptic approach, X-ray, and positive pressure 
ventilation
During the late nineteenth century, Joseph Lister, based on Louis Pasteur’s 
theory of micro-organisms, introduced the concept of asepsis in 1867. Surgeon’s 
hands, instruments, and surgical wounds were sterilized with 5% carbolic acid 
(phenol) solution and a mist of phenol was sprayed into the surgical field [5]. This 
policy led to an extreme reduction of post-operative mortality and for this reason, 
Lister is regarded as the father of modern surgery. Caroline Hampton, chief nurse 
and later on the wife of William Halsted, one of the founding fathers of the John’s 
Hopkins Hospital, developed severe dermatitis due to frequent exposure to phenol 
and mercuric chloride. This provoked Halsted to ask the Goodyear Company to 
develop rubber gloves to protect the hands of the surgical team. These became avail-
able at the end of 1890 and were soon used throughout the world [6].
The aftermath of the nineteenth century saw the discovery of X-ray by William 
Konrad Rontgen in 1895. For the first time in mankind, it became possible to 
identify large tumors in the chest when not shaded by the heart and other mediasti-
nal structures. At the turn of the twentieth century, the major barrier to enable one 
stage intrathoracic surgery was that of the open pneumothorax. This is remarkable 
since the anatomist Vesalius in 1543 had extensively studied respiration and already 
studied tracheotomy and positive pressure ventilation. His ideas would be dormant 
for about 3.5 centuries [7]. Based on this concept that there should be a pressure 
difference between the intra-alveolar pressure and the atmospheric pressure, 
Sauerbruch, still an assistant of von Mikulicz, developed the negative pressure 
chamber [8]—a genius idea, but quite unpractical. Only two of these operation 
theaters were built worldwide, one in Germany and the other one in the German 
Hospital (today the Lenox-Hill hospital) in New York where the surgeon Willy 
Meyer, emigrated to the USA from Germany in 1884, added a small positive pres-
sure chamber over the patients head in 1909, this was called the super chamber but 
it was never clinically used [10]. Willy Meyer would become one of the founding 
fathers of the American Association for Thoracic Surgery (AATS) in 1918.
In the same year, 1909, and also in New York, Meltzer and his son-in-law Auer 
launched their concept of positive pressure ventilation, using a flexible silk woven 
tracheal catheter and a continuous stream of air mixed with ether [9]. Their 
concept was the birth of modern anesthesia. Recognizing that this was an enormous 
step forward, Meltzer was invited to become the first president of the AATS. In a 
speech delivered at the founding meeting of the AATS, Willy Meyers stated: “The 
thorax was the last fortress to be attacked and it has been laid open safely to the 
surgeon’s knife” [10].
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2.2 Smoking induced global lung cancer epidemic
Lung cancer was a very rare disease in the beginning of the twentieth century. 
In 1919, Alton Ochsner, as a medical student was invited with his whole class to 
witness an autopsy of a patient who died of lung cancer. The pathologist announced 
that no one in that class would ever again see another such case [11]. It took 17 years 
before Ochsner, who had become a surgeon, saw his second case, followed by 8 
other cases in the 6 following months. All of these patients were male and had 
served as soldiers in World War I and in the line of duty they had taken up the 
habit of smoking, provoked by mass advertisements promoting smoking. Ochsner 
was amongst the first surgeons to correlate smoking to the development of lung 
cancer [12]. With the lung cancer epidemic which started after World War I, the 
number of patients with potentially resectable lung cancer increased significantly. 
Two major surgical items had to be settled; should a lung resection for cancer be 
a lobectomy or a pneumonectomy and what is the best surgical technique? Is it 
mass hilar ligation or anatomical dissection? The first report on lobectomy for 
lung cancer was that of Edward Churchill (Boston) in 1932 [13]. One year later, 
Evarts Graham, while intending to perform a lobectomy, was forced to perform a 
pneumonectomy because the tumor was very centrally located in the hilum at the 
origin of the left upper lobe (bronchoplastic procedures such as sleeve resection 
had not been developed yet) [14]. For a considerably long period, pneumonectomy 
was regarded as the golden standard for all lung cancer patients. Lobectomy by 
many was considered inferior and compared with lumpectomy without resection 
of loco-regional lymph nodes in breast cancer [15]. Only in 1962, a large case series 
between pneumonectomy and lobectomy were compared showing that lobectomy 
was equivalent to pneumonectomy as a cancer operation but with a lower rate of 
complications and mortality [16].
2.3 Fundamental steps in the development of state-of-the-art lung surgery
With respect to surgical technique, there was no consensus on hilar control; 
mass ligation or anatomical dissection and step-by-step control of the hilar struc-
tures. Cadaveric studies performed by Blades and Kent in the early 1940s pushed 
the world toward the latter, later supported by several publications of Boyes on the 
intrahilar anatomy of the lung segments [9, 17].
With this knowledge, Clement Thomas Price (London, 1947) introduced 
the concept of parenchyma sparing operations, having done the first anatomi-
cal segmentectomy in a lung cancer patient [18]. The first sleeve resection for 
bronchogenic carcinoma was performed in 1952 [19]. Consequently, it was around 
the mid-1950s the four main operations in lung cancer as we know today were in 
the armamentarium of the thoracic surgeon: pneumonectomy, lobectomy, sleeve 
lobectomy, and segmentectomy.
A major step forward was the introduction of double lumen endo-tracheal tube 
by Carlens in 1949 [20]. With this selective single lung ventilation concept, modern 
lung surgery is greatly facilitated, particularly, the endoscopic and robotic tech-
niques used nowadays (discussed later in this chapter).
Diagnostic techniques were still very primitive in that era compared with today’s 
standards. Besides standard chest X-ray, there was rigid bronchoscopy, bronchog-
raphy, planography, and cytology. The concept of staging had to be developed yet. 
Exploratory thoracotomy in “operable patients” was performed with a very low 
threshold, not to lose time. Some authors reported up to 50% inoperability [21]. 
In the Amsterdam University Hospital between 1955 and 1960 in a series of 100 
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exploratory thoracotomies in patients who were found to be inoperable, 54% of 
patients had complications and 9 of the 100 patients died due to post-operative 
complications [22]. In 63% of the cases, mediastinal ingrowth or large irresectable 
nodes were found. In 23%, there was in growth in heart and/or major vessels, 12% 
ingrowth into the thoracic wall, 1% in growth in the diaphragm, and 1% pleural car-
cinomatosis. By far, mediastinal involvement was the leading cause of inoperability. 
In 1959, Carlens had published his experience with 100 mediastinoscopies [20]. The 
morbidity of this technique was 2.5% and the mortality was less than 0.5%, way 
better then exploratory thoracotomy. The Amsterdam team embraced mediasti-
noscopy and combined this in a series of operable patients with bronchoscopy and 
on indication diagnostic pneumothorax. Due to the mediastinoscopy findings, the 
resection rate in Amsterdam rose from 60 to 94% with 12% false positive medias-
tinoscopies [20]. Years later, in 1984, Griffith Pearson published a landmark paper 
showing that when positive mediastinal nodes were found, any subsequent lung 
resection would not cure a patient [23].
The world was waiting for methods to better identify loco-regional progression 
and distant metastases. Hounsfield, by combining tomography images with the 
calculating power of a computer, constructed the first computed tomography (CT) 
scanner, first for brain scans only, but in 1975 he and his team built the first whole 
body scanner. The computed tomography (CT) scanner was soon to be followed 
by the magnetic resonance imaging (MRI) scanner in 1977, while the next big step 
was the combination of positron emission tomography (PET) and CT scanners in 
1991. The use of mediastinoscopy has declined after the introduction of ultrasound-
guided examinations of the mediastinum and the hilum (endo-esophageal ultra-
sound (EUS) and endo-bronchial ultrasound bronchoscopy (EBUS)), but is still 
used on a regular base when the latter techniques fall short.
2.4 The rise of minimally invasive lung surgery
For decades, postero-lateral thoracotomy has been the preferred entrance for 
most lung resections (Figure 1A). However, the price of an excellent exposure to 
the lung hilum came with high percentages of long standing post-operative pain, 
discomfort, and functional loss.
The Swedish internist Jacobeus is often positioned as the founding father of tho-
racoscopy but in fact, it was the British surgeon Francis Richard Cruse who already 
had published this technique in 1865 [24].
The first thoracoscopic resections were not immediately embraced by the surgical 
community. Ralph Lewis was the first one to publish a series of 100 lobectomies 
done thoracoscopically [25]. Lacking experience, tailor-made instruments, and 
specific endo-staplers, these resections were performed using a mass stapling 
technique. In Los Angeles, Robert McKenna worked out a standardized approach for 
video-assisted thoracic surgery (VATS) lobectomy (Figure 1B), working through the 
hilum from anterior to posterior; in 2006, he published a series of 1100 cases [26].
This provoked surgeons around the world to adapt this technique and today 
in many hospitals, it is the preferred approach for the majority of cases. In 2019, 
Eric Lim published the results of the VIOLET trial, a prospective randomized 
trial between VATS and thoracotomy in lung cancer patients. VATS showing to be 
superior with respect to major adverse events, less pain on post-operative day 2 and 
shorter median hospital stay with an equal oncological outcome (number of lymph 
nodes harvested and upstaged and R-0 resections) [27].
Studies on chronic pain (pain for which patients visit a doctor 3 months post-
operative), however, did not show a major difference in pain between thoracotomy 
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patients and VATS patients 3–6 months post-operatively [28]. Chronic pain after 
VATS is often contributed to the insult of multiple intercostal nerves by trocars 
and instruments. It has to be seen whether the explanation is that simple, however, 
it moved surgeons to search for even less invasive methods, eventually leading 
to the concept of uniportal VATS (UVATS), first proposed by Rocco in 2004 [29] 
(Figure 1C).
There is still no proof that an UVATS approach leads to less pain, discomfort, 
and loss of functionality compared with multiple port VATS.
With the idea of intercostal nerve damage in mind, surgeons have also explored 
other VATS-assisted intrathoracic pathways like subxiphoid and cervical approaches 
[30, 31]. Others are exploring a hybrid approach, combining 5 mm intercostal ports 
with a subxiphoid approach [32].
Figure 1. 
Overview of the surgical approaches for treatment of lung cancer. (A) Postero-lateral thoracotomy, (B) 3 ports, 
video-assisted thoracic surgery (VATS), (C) uniportal video-assisted thoracic surgery (UVATS), (D) robotic-
assisted thoracic surgery (RATS), and (E) endo-bronchial surgery.
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Almost parallel with the introduction and evolution of VATS, the world saw the 
introduction of robotic-assisted thoracic surgery (RATS), first published by Franca 
Melfi and her team [33] (Figure 1D).
Up till now, no significant differences have been shown in complications and 
outcome between VATS, UVATS, and RATS [34]. The major reason that the intro-
duction of RATS lagged behind in many institutions is a financial reason; it is not 
cost-efficient. In the meantime, VATS has evolutionized to three-dimensional VATS 
(3D VATS) and robotic-like instruments have become available for laparoscopic and 
VATS procedures.
2.4.1 Sub-lobar resection: the rise of segmentectomy
During the last decade, there is a growing interest in lung parenchyma-sparing 
resections. This need is more highlighted by the results of the two largest popula-
tion based national screening studies (NLST, 2011 and NELSON, 2018) showing 
that discovery and resection of early stage lung cancer through screening programs 
lead to significantly better survival of patients [35, 36]. The NLST study showed a 
reduction of 20% in lung cancer mortality for annual screening over 3 years with 
low-dose CT with a greater benefit for screening in women. The NELSON study 
showed for screening with low-dose CT, a 26% reduction of lung cancer mortality 
in high-risk men and up to 61% reduction of lung cancer mortality in high-risk 
women over a 10-year period. Nowadays, there is a trend toward sub-lobar resec-
tion as segmentectomy, making the oncological lung surgery even more challeng-
ing. Moreover, this makes the role of peri-operative diagnostic tools as fluorescent 
indocyanine green (ICG) [37], 3D-CT modalities, and (navigational) bronchoscopy 
interventions (next section, Figure 1E) indispensable. Because of its anatomical 
complexity, many surgeons hesitate to perform segmentectomy. For this reason, 
in 2012, Hiroaki Nomori and Morihito Okada published the book “Illustrated 
Anatomical Segmentectomy for Lung Cancer” which is an essential book for sur-
geons starting a segmentectomy program at their centers. In 2019, segmentectomy 
is mostly performed in countries of Eastern Asia, such as Japan, followed by few 
centers in the USA and Western Europe.
3.  Advances in thoracic imaging facilitating minimally invasive lung 
surgery: a brief outlook into the future
Over the past few decades, imaging modalities such as CT, PET-CT, and standard 
chest X-ray imaging have played a key role in the non-invasive diagnostic work-up 
of thoracic disease. In addition, these imaging modalities are an essential part of the 
preoperative planning process of thoracic surgical procedures. Even though there 
is a broad range of clinical indications for various thoracic imaging modalities and 
the information provided by all different modalities is different, the purpose of 
this section is not to undertake a comprehensive evaluation of the characteristics of 
these imaging modalities. Specifically, this section will focus on innovative preop-
erative and intraoperative imaging modalities as a surgical planning and naviga-
tion tools and provide a brief overview of new developments in medical imaging, 
especially in the context of (oncologic) pulmonary resections.
3.1 Three-dimensional computed tomography (3D-CT)
In the setting of oncologic thoracic surgery, a standard chest CT scan can be 
used to evaluate the extensiveness of disease in terms of pleural, mediastinal, chest 
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wall, or vascular involvement. In addition, the CT scan is used to study the surgical 
anatomy of the pulmonary artery (and its major branches), pulmonary vein, and 
bronchial structures when a resection of the lung parenchyma is planned. Due to 
the establishment and development of more modern multislice CT scanners, it has 
become easier to detect smaller peripheral tumors. While this has enabled more 
diagnostic accuracy, it has resulted in an increased clinical use of sublobar anatomic 
resections. Specifically, in the setting of anatomic segmental pulmonary resections, 
which are technically and anatomically more demanding and complex, there is a 
need for more accurate imaging modalities that enables better preoperative knowl-
edge of the surgical anatomy (such as bronchial and vascular anatomy in sublobar/
segmental levels). Recently, an increasing number of scientific reports have been 
published on the use of preoperative three-dimensional (3D)-CT reconstruction as 
a surgical planning tool before anatomic resection of pulmonary segments or lobes 
[38–42]. According to some of these studies, the preoperative use of 3D-CT recon-
structed images is feasible and safe and, in some cases, associated with shorter oper-
ative time due to better preoperative understanding of surgical anatomy [38, 42]. In 
order to obtain 3D-CT image reconstructions, different methods are described and 
various (free open-source) software packets are available [42–44]. However, there 
are also limitations regarding the utility of software to reconstruct 3D images of CT 
scans. For example, the identification and separation of the pulmonary artery and 
vein may be a challenging and time-consuming process. Moreover, in some cases, 
a contrast-enhanced CT scan is required to create 3D-simulations, which increases 
the risks of radiation exposure. In addition, the reconstruction commonly requires 
technical support and the assistance of radiology and information and communica-
tion technology (ICT) experts.
Oizumi et al. reported a study on the use of 3D reconstruction of multidetector 
CT (MDCT) images in order to plan and guide pulmonary segmentectomy preop-
eratively and during surgery [38]. It was noted that after the introduction of 3D-CT 
reconstruction, the number of (fairly) difficult classified segmentectomies that have 
been performed increased significantly, suggesting that preoperative 3D-CT simula-
tion contributes fairly to the efficacy of surgical planning of complex segmentecto-
mies. In addition, in a retrospective analysis of patients undergoing thoracoscopic 
segmentectomy reported by Xue et al., the authors found that when preoperative 
3D-CT reconstruction was used to make operation plans, in 19% of the cases, the 
operation plan was changed due to the results of 3D simulation [42]. The original sur-
gical plan of these cases was changed due to the expectation of an inadequate resec-
tion margin distance, based on pre-operative simulation results. This indicates that 
preoperative 3D simulation not only contributes to technical feasibility and efficacy 
of surgery, but also to the decision-making process from an oncological point of view.
Even though an increasing number of studies on the use of 3D-CT simulation are 
being published, the majority of them do not report on the differences in param-
eters of clinical outcome (such as perioperative blood loss, post-operative stay, and 
conversion rates to thoracotomy) but focus more on technical aspects and feasibility 
of 3D-simulation and surgery. However, the majority of reports do recognize the 
following advantages of preoperative 3D-simulation in the context of (sub-)lobar 
pulmonary resection: (1) classification and identification of anatomical (vascular 
and bronchial) abnormalities; (2) identification of unsuitable surgical cases for 
segmentectomy; (3) training of less experienced thoracic surgeons and surgical 
residents; (4) preoperative estimation of proper surgical resection margin; (5) a step-
wise preoperative surgical planning; and (6) intraoperative navigation for identifica-
tion of anatomical structures [38, 40–42].
3D-CT-mediated preoperative surgical planning and intraoperative guidance of 
(oncological) pulmonary surgery could contribute significantly to the development 
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of more accurate and safer (sublobar) anatomic resections. In the near future, this 
technology will become more common in thoracic surgery. However, in order to 
reach that stage, some (mostly technical) limitations need to be overcome.
3.2 Virtual reality, augmented reality, and mixed reality
Virtual reality (VR) is a technology that enables users to interact with a com-
puter-generated virtual 3D interface (Figure 2). More interestingly, in augmented 
reality (AR), the user is able to overlay aspects of the VR world within the real 
physical world. Finally, mixed reality (MR) allows users to create a hybrid physical 
and virtual world and offers the possibility to interact and analyze objects in the 
physical world by virtual projections [45, 46].
Recently, surgical intraoperative navigation as well as preoperative surgical 
simulation based on VR, MR, and AR have been developed and successfully used 
in various surgical fields including neurosurgery, liver surgery, kidney surgery, 
and orthopedic surgery [47–51]. In contrast to 2D interfaces (e.g. conventional CT 
scans), VR, MR, and AR enable not only visualization of anatomical structures 
but also allow interactive manipulation of the digital information (e.g. anatomic 
structures) provided by (wearable) computer-integrated devices (such as the 
Microsoft Hololens or the Google Glass). It has been suggested that these new 
interfaces might have the potential to benefit both the surgeon and the patient. 
For surgeons, this benefit comes by the way of improved preoperative surgical 
planning, better and more accurate intraoperative imaging guidance, and a bet-
ter preoperative awareness of anatomical abnormalities. Patients will potentially 
benefit from shorter operative time, shorter length of hospital stay, and improved 
outcomes. Additionally, AR, VR, and MR offer the possibility to simulate surgical 
situations as well as facilitating training for surgeons and residents. In the field of 
thoracic surgery, some of these modalities have been used over the past few years in 
order to train surgical residents and surgeons to master the techniques necessary for 
minimally invasive lung surgery [52].
However, only very few reports are available on the use of AR, VR, or MR for 
surgical planning or intraoperative navigation for lung surgery [53–55]. Frajhof 
Figure 2. 
An example of virtual reality application during minimally invasive lung cancer surgery in the operating 
theater.
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et al. recently published a study on the use of AR, VR, and MR technology in the 
preoperative planning of a technically demanding VATS left upper lobectomy [53]. 
In another study from Rouzé et al., augmented reality was used as a navigation tool 
in combination with cone beam CT (CBCT) to guide intraoperative localization 
of pulmonary nodules for wedge resection through VATS. The investigators firstly 
localized the lesions by CBCT intraoperatively. Subsequently, a 3D reconstruction 
of the nodule was created by using software. After this, an augmented fluoroscopic 
3D image of the pulmonary nodule was projected on a screen in front of the operat-
ing table. By this, the surgeon was able to localize the lesion intraoperatively and 
perform a wedge resection safely [54].
Interestingly, also some reports are available on the use of VR 3D reconstruction 
of the airways, known as virtual bronchoscopy, specifically used as a diagnostic aid 
tool in the assessment of airway masses and stenosis [56, 57]. Virtual bronchoscopy 
contributes fairly to the diagnostic process since it enables diagnostic maneuvers, 
such as assessing bronchial anatomy distally from stenoses, which are not possible 
with standard flexible bronchoscopy. Moreover, virtual bronchoscopy is a noninva-
sive method and does not bear any additional risks (e.g. radiation exposure or iatro-
genic airway damage) for patients. Despite these advantages, virtual bronchoscopy 
is not expected to completely replace flexible bronchoscopy due to some limitations. 
For example, tumor boundaries can be misjudged by intrabronchial secretions that 
might lead to a false-positive result. Moreover, it has shown not to be sensitive and 
effective enough for detecting small mucosal abnormalities (e.g. erythema and 
erosion), dynamic stenoses (caused by, for example, the respiratory cycle or vocal 
cords), and in differentiating mucus plugs from a mass. Finally, virtual bronchos-
copy has the limitation that it does not enable biopsies.
4.  Advances in the armamentarium of (the endo-bronchial) lung  
cancer surgery
In the past two decades, there has been an increase in the development of 
innovative technologies to facilitate more accurate, efficient, and safe (minimally 
invasive) thoracic interventions. Specifically, there have been some reports on the 
progress of innovative therapeutic modalities that approach lung cancer through 
other minimally invasive methods than direct surgery. Examples of these therapeu-
tic options are thermal ablation, including radiofrequency ablation (RFA), micro-
wave ablation (MWA), and cryoablation of malignant lung lesions. This section 
will touch on some of these developments and review some outcomes of thermal 
ablation therapy.
4.1 Thermal ablation therapy
4.1.1 Radiofrequency ablation (RFA)
Amongst various thermal ablation therapies, RFA is a well-studied method, 
especially in the treatment of liver cancer [58, 59]. Due to favorable outcomes in the 
treatment of liver cancer, specifically hepatocellular carcinoma, the application of 
this technology to malignant lesions in other organs, including the lungs, has been 
growing. RFA involves the insertion of a probe inside the affected target tissue. The 
electrode on the probe generates frictional heat that creates coagulation necrosis 
of the surrounding (tumor) lung parenchyma. In pulmonary surgery, the use of 
RFA has been reported in the treatment of various malignant lesions including 
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inoperable lung cancer [60–62], primary or metastatic pulmonary tumors of less 
than 3.5 cm in size [63], and stage I-4 non-small cellular lung cancer (NSCLC) not 
eligible for surgery [64–67]. Results from retrospective studies on RFA of primary 
malignant lung lesions have suggested reasonable overall 1-year survival rates 
ranging from 78 to 94% in patients with early stage lung cancer [66, 68–70]. A 
5-year survival rates have been reported to be significantly lower and in the range 
of 25–58% [66, 71, 72]. Important prognostic factors in RFA therapy of lung cancer, 
in terms of survival, are the additional use of targeted systemic therapies, lesions 
less than 3 cm (diameter), a Charlson comorbidity index (an index of associated 
comorbidities) >5, and lower stage disease [66, 73].
A major drawback of RFA therapy compared with surgical resection is the poor 
results of local progression control [74]. This limitation might be explained by the 
fact that in RFA therapy no systematic lymph node dissection is carried out and, 
additionally, no good method exists to check for local adequate treatment margins. 
With regard to complications, pneumothorax is one of the most common complica-
tions associated with RFA. However, it is most often (>80%) treated conservatively 
without the need for chest tube drainage [75]. In addition, pleural effusion might 
develop after RFA, however, similar to pneumothorax, does not often (<5%) require 
intervention [75]. In summary, RFA therapy seems an effective and relatively safe 
intervention for treating lung cancer, however, a careful patient selection is neces-
sary. Moreover, more future long-term and large randomized controlled trials are 
necessary to compare the clinical outcomes between RFA, surgical resection, and 
other modalities of thermal ablation therapy.
4.1.2 Microwave ablation (MWA)
MWA involves hyperthermia-mediated ablation of tissue by causing friction 
between water molecules in the target tissue. By creating a dipole excitation, 
hyperthermia is generated and coagulation necrosis results in the lesion and 
surrounding tissue [76, 77]. The placement of the probes is commonly guided by 
CT/CT-fluoroscopy. MWA has been successfully used to create larger ablation 
zones than RFA. Compared with RFA, MWA technology is thought to be more 
effective in creating larger zones of coagulation necrosis due to the elimination 
of heat loss through heat sink (the loss of heat through blood flow inside the 
target tissue) [76].
Studies and long-term data after MWA as a thermal ablation modality are 
limited when compared with RFA. In a recent review, Yuan and colleagues reported 
a meta-analysis of clinical outcomes after RFA and MWA for primary and meta-
static pulmonary malignancies [75]. The authors identified 11 studies based on 
MWA compared with 42 studies based on RFA therapy, all with a retrospective 
study design. In this meta-analysis, it was demonstrated that RFA seems to be 
superior to MWA with regard to overall survival (up to 5 years) for both primary 
and metastatic pulmonary malignancies. However, the authors note that the results 
of lung metastasis should be interpreted carefully, since small groups of patients 
were included in the analysis based on only a few retrospective studies. With regard 
to local tumor progression free survival, RFA and MWA showed similar results. In 
addition, similar to RFA, MWA is a relatively safe intervention which is not associ-
ated with high complication rates. Yuan et al. reported comparable rates of pneu-
mothorax and pleural effusion after ablation by MWA and RFA [75]. Concerning 
prognostic factors negatively affecting survival and local tumor progression 
control, more advanced disease stage, tumors >3 cm (diameter), and emphysema-
tous lungs have been identified [78].
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4.1.3 Cryoablation
An opposite method of hyperthermia induced ablation, termed cryoablation, 
creates protein denaturation, ischemia, cell rupture, and necrosis through local 
hypothermia (temperatures < −40°C) [79]. In this technique, compressed argon 
gas is used to create freezing temperatures that induce local injury to the tissue. 
Subsequently, helium is used to thaw the tissue. Comparable to MWA, in cryoabla-
tion, multiple probes can be used to increase the ablation area in the tissue and 
placement under the guidance of CT/CT-fluoroscopy. Although cryosurgery is a 
relatively old ablative technique, use of cryoablation in the context of lung cancer 
and long-term studies are limited. Besides percutaneous cryoablation, other meth-
ods of cryoablative strategies are endo-bronchial (for obstructive intrabronchial 
tumors) (Figure 1E) and intrathoracic (during surgery). Specific indications for 
each modality have been reviewed by Niu and colleagues and are beyond the scope 
of this chapter [80].
Since thermal ablation therapies are commonly reserved for patients not eligible 
for curative surgery, tumor recurrence after radiotherapy or patients who refuse 
surgery, even though they have resectable lesions, cryoablation is often offered as 
a therapy to palliate symptoms or to increase survival in advanced disease stage. 
Consequently, a number of reports have been published on the use of cryoablation 
for the treatment of medically inoperable NSCLC, advanced stages of NSCLC, and 
for pulmonary metastasis [80–84]. Niu et al. reported on a series of 840 patients 
with NSCLC who received percutaneous cryoablative therapy for various stages of 
NSCLC ranging from IIa to IV. The reported overall survival was 68, 52, 34, 26, and 
17% for 1-, 2-, 3-, 4-, and 5-year, respectively. Local and peripheral recurrence rates 
were 28.3 and 47.2%, respectively, after a median follow-up of 34 months (range 
4–63 months). For patients with less advanced NSCLC, better outcome is reported 
in terms of overall survival. In 2012, Yamauchi et al. demonstrated a 2-year overall 
survival of 88% in medically inoperable patients with stage I NSCLC who were 
treated with percutaneous cryoablation [84]. In addition, Moore and colleagues 
published a study in which an overall survival rate of 67.8% was reported in patients 
with stage I NSCLC after 5 years [82].
Regarding cryoablation therapy in metastatic lung lesions, studies have 
also proven the efficacy and safety of percutaneous cryoablation. For example, 
Yamauchi et al. reported a 3-year progression free survival rate of 59% for patients 
with metastatic colorectal carcinoma treated with cryoablation [85]. Factors associ-
ated with local tumor progression or poor prognosis have been studied by multi-
variate analyses. Interestingly, most of these factors (e.g. tumor size <3 cm and stage 
of disease) are comparable to the factors in other modalities of thermal ablation 
[78, 80]. Regarding the safety profile of cryoablation compared with other modali-
ties of thermal ablation, comparable rates of pneumothorax and pleural effusion 
are reported in the literature [77, 80]. However, incidental reports of transient 
recurrent laryngeal nerve neuropraxia have also been documented [86].
5. Conclusions
Until the late nineteenth century, the inside of the chest cavity was a no-go area 
for complex surgical interventions. The world still was not ready yet for primary lung 
resections. To make the lung surgery possible, several giant steps were undertaken: 
the introduction of aseptic concept by Joseph Lister in 1867, the discovery of X-ray by 
William Konrad Rontgen in 1895, and the introduction of positive pressure ventilation 
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by Meltzer and Auer in 1909. With the lung cancer epidemic after World War I, the 
number of patients with potentially resectable lung cancer increased significantly. 
Surgeons around the world were debating on the preferable resection (lobectomy vs. 
pneumonectomy) and the best surgical technique: mass hilar ligation versus anatomi-
cal dissection. While the first report on lobectomy for lung cancer in 1932, it took 
almost 30 years to report that lobectomy was the preferred resection for lung cancer 
surgery. In the same period, the anatomical dissection technique gained wider applica-
tion. This all together with the discovery of double lumen endo-tracheal tube by 
Carlens in 1949 paved the way for modern lung resection techniques. The introduction 
of diagnostic tools as CT, MRI, PET-CT, and later EUS and EBUS facilitated even bet-
ter tumor localization and mediastinal evaluation decreasing the surgical mortality.
The next major challenge was decreasing the morbidity of thoracotomy: high 
percentages of long standing post-operative pain, discomfort, and functional loss. 
The solution led to the development of modern minimally invasive lung surgery. In 
2006, Robert McKenna published a standardized approach for VATS lobectomy in 
a series of 1100 cases leading to global adaptation of VATS for lung surgery. While 
VATS showing to be superior with respect to major adverse events, less pain on 
post-operative day 2 and shorter median hospital stay with an equal oncological 
outcome, studies on chronic pain, however, did not show a major difference in pain 
between thoracotomy and VATS. This moved surgeons to search for even less inva-
sive methods, eventually leading to the concept of uniportal VATS, first proposed 
by Rocco in 2004, subxiphoid and cervical approaches, and hybrid approach com-
bining 5 mm intercostal ports with a subxiphoid approach. At the same time, the 
world witnessed the introduction of RATS by Franca Melfi and her team, however, 
because of the financial reasons, the introduction of RATS in many centers lagged 
behind. In the meantime, VATS has evolutionized to 3D-VATS and robotic like 
instruments have become available for laparoscopic and VATS procedures. Whether 
all these approaches will lead to reduction of chronic pain is yet to be determined.
The results of major screening programs have shifted the trend of lung resec-
tion toward sub-lobar resection as segmentectomy, making the lung surgery even 
more challenging. Moreover, this makes the role of peri-operative imaging tools 
as fluorescent indocyanine green (ICG), 3D-CT modalities, and (navigational) 
bronchoscopy interventions indispensable.
The upcoming VR, AR, and MR enable a more naturalistic 3D presentation of 
human anatomy in a digital interface. As a diagnostic tool, it can provide physicians 
with a more realistic view of the patient’s anatomy and might enable diagnostic 
assessment, preoperative surgical planning, and intraoperative guidance. In addi-
tion, it can provide training and learning platform for students, residents, and sur-
geons. It has already proven its added value for a broad range of surgical procedures; 
however, AR/VR/MR has not been used widely in thoracic surgery yet. Considering 
the speed of development of this technology in other areas, it is expected that it will 
make its way into the world of thoracic surgery in the near future. In this perspec-
tive, hybrid operating theaters including 3D-CT and (robotic-assisted) navigational 
bronchoscopy tools are already on their way. To address this, however, it is essential 
that thoracic surgeons have an active and open attitude toward the introduction of 
innovative (digital) applications.
With respect to endo-bronchial interventions, thermal ablation therapy seems 
to provide an efficacious and safe alternative for surgical therapy of lung cancer 
and lung cancer metastasis. However, patient’s selection should be carried out 
with caution and should be personalized for each patient based on type of cancer 
(e.g. NSCLC), comorbidities, tumor size, and disease stage. Specifically, thermal 
ablation therapy could offer a palliative or even a life-prolonging treatment option 
for non-surgical candidates. Hopefully future long-term and larger prospective 
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(randomized controlled) trials will answer the remaining questions. For example, 
it will be necessary to study the impact of combining thermal ablation therapy with 
other conventional (e.g. systemic or radiotherapy) therapies for the treatment of 
lung cancer. In addition, more data are warranted on the determination of the best 
therapy for incomplete ablations and/or local recurrence of disease. More interest-
ingly, biomarkers or novel imaging techniques to follow-up on ablative therapies are 
also required, especially since the radiological follow-up of recently ablated lung 
tissue is very challenging. More data and confirmation of these data are therefore 
necessary and need to be generated by future multicenter trials.
To conclude, this chapter provides a historical overview and a summary of 
state-of-the-art surgical techniques in the treatment of lung cancer today. The 
journey of lung surgery was and is a very challenging one, with major hurdles to 
overcome. It departed from a “no-go” era, leaving behind the golden standard 
of pneumonectomy and thoracotomy, to arrive in the current era of minimally 
invasive and robotic-assisted surgery. The journey continues toward the horizon of 
non-intubated operations, sub-lobar resections, virtual reality imaging modalities, 
navigational bronchoscopy interventions, and hybrid procedures. We are heading 
toward the era of incisionless, natural orifice surgery: an almost science fiction 
vision, yet nothing is more real.
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